Cantargia
Lund
About Cantargia
The company is based on the original discovery that leukemic stem cells in patients with chronic myeloid leukemia (CML) express a cell-surface receptor, whereas corresponding normal hematopoietic stem cells do not express this receptor. Stem cells from patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) has also been shown to have and upregulation of the receptor. Cantargia uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $28.4M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jun 2025)
- Ticker: fra:7V3
- Website: cantargia.com
- Phone: +46 4 62 75 62 60
Industries & Categories
Biotechnology, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cantargia-96378 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.